Skip to main content
Erschienen in: Current Allergy and Asthma Reports 11/2015

01.11.2015 | Rhinosinusitis (J Mullol, Section Editor)

Antileukotrienes in Upper Airway Inflammatory Diseases

verfasst von: Cemal Cingi, Nuray Bayar Muluk, Kagan Ipci, Ethem Şahin

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Leukotrienes (LTs) are a family of inflammatory mediators including LTA4, LTB4, LTC4, LTD4, and LTE4. By competitive binding to the cysteinyl LT1 (CysLT1) receptor, LT receptor antagonist drugs, such as montelukast, zafirlukast, and pranlukast, block the effects of CysLTs, improving the symptoms of some chronic respiratory diseases, particularly bronchial asthma and allergic rhinitis. We reviewed the efficacy of antileukotrienes in upper airway inflammatory diseases. An update on the use of antileukotrienes in upper airway diseases in children and adults is presented with a detailed literature survey. Data on LTs, antileukotrienes, and antileukotrienes in chronic rhinosinusitis and nasal polyps, asthma, and allergic rhinitis are presented. Antileukotriene drugs are classified into two groups: CysLT receptor antagonists (zafirlukast, pranlukast, and montelukast) and LT synthesis inhibitors (5-lipoxygenase inhibitors such as zileuton, ZD2138, Bay X 1005, and MK-0591). CysLTs have important proinflammatory and profibrotic effects that contribute to the extensive hyperplastic rhinosinusitis and nasal polyposis (NP) that characterise these disorders. Patients who receive zafirlukast or zileuton tend to show objective improvements in, or at least stabilisation of, NP. Montelukast treatment may lead to clinical subjective improvement in NP. Montelukast treatment after sinus surgery can lead to a significant reduction in eosinophilic cationic protein levels in serum, with a beneficial effect on nasal and pulmonary symptoms and less impact in NP. Combined inhaled corticosteroids and long-acting β-agonists treatments are most effective for preventing exacerbations among paediatric asthma patients. Treatments with medium- or high-dose inhaled corticosteroids, combined inhaled corticosteroids and LT receptor antagonists, and low-dose inhaled corticosteroids have been reported to be equally effective. Antileukotrienes have also been reported to be effective for allergic rhinitis.
Literatur
1.
Zurück zum Zitat Elnabtity MH, Singh RF, Ansong MA, Craig TJ. Leukotriene modifiers in the management of asthma. J Am Osteopath Assoc. 1999;99(7):S1–6.PubMed Elnabtity MH, Singh RF, Ansong MA, Craig TJ. Leukotriene modifiers in the management of asthma. J Am Osteopath Assoc. 1999;99(7):S1–6.PubMed
2.
Zurück zum Zitat Peters-Golden M, Gleason MM, Togias A. Cysteinylleukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy. 2006;36(6):689–703.PubMedCentralCrossRefPubMed Peters-Golden M, Gleason MM, Togias A. Cysteinylleukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy. 2006;36(6):689–703.PubMedCentralCrossRefPubMed
4.••
Zurück zum Zitat Cobanoğlu B, Toskala E, Ural A, Cingi C. Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2013;13(2):203–8. doi:10.1007/s11882-013-0341-4. Antihistamines and leukotriene receptor antagonists in mono- or combination therapy are commonly used in the treatment of allergic rhinitis. CrossRefPubMed Cobanoğlu B, Toskala E, Ural A, Cingi C. Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2013;13(2):203–8. doi:10.​1007/​s11882-013-0341-4. Antihistamines and leukotriene receptor antagonists in mono- or combination therapy are commonly used in the treatment of allergic rhinitis. CrossRefPubMed
5.
Zurück zum Zitat Haberal I, Corey JP. The role of leukotrienes in nasal allergy. Otolaryngol Head Neck Surg. 2003;129(3):274–9.CrossRefPubMed Haberal I, Corey JP. The role of leukotrienes in nasal allergy. Otolaryngol Head Neck Surg. 2003;129(3):274–9.CrossRefPubMed
7.
Zurück zum Zitat Szczeklik A, Mastalerz L, Nizankowska E, Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin induced asthma. Am J Respir Crit Care Med. 1996;153:567–71.CrossRefPubMed Szczeklik A, Mastalerz L, Nizankowska E, Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin induced asthma. Am J Respir Crit Care Med. 1996;153:567–71.CrossRefPubMed
8.
Zurück zum Zitat Peters-Golden M, Henderson Jr WR. The role of leukotrienes in allergic rhinitis. Ann Allergy Asthma Immunol. 2005;94(6):609–18.CrossRefPubMed Peters-Golden M, Henderson Jr WR. The role of leukotrienes in allergic rhinitis. Ann Allergy Asthma Immunol. 2005;94(6):609–18.CrossRefPubMed
9.
Zurück zum Zitat Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest. 2005;127(4):1312–26.CrossRefPubMed Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest. 2005;127(4):1312–26.CrossRefPubMed
10.
Zurück zum Zitat Bäck M, Dahlén SE, Drazen JM, et al. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev. 2011;63(3):539–84.CrossRefPubMed Bäck M, Dahlén SE, Drazen JM, et al. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev. 2011;63(3):539–84.CrossRefPubMed
11.
Zurück zum Zitat Baççioglu A, Yorgancioglu A, Cingi C, Cuhadaroglu C. Role of leukotriene antagonists and antihistamines in treatment of allergic rhinitis and asthma comorbidity. J Med Updates. 2013;3(1):34–9.CrossRef Baççioglu A, Yorgancioglu A, Cingi C, Cuhadaroglu C. Role of leukotriene antagonists and antihistamines in treatment of allergic rhinitis and asthma comorbidity. J Med Updates. 2013;3(1):34–9.CrossRef
12.••
Zurück zum Zitat Sanak M. Antileukotrienes in the treatment of allergic rhinitis. Global Atlas Of Allergic Rhinitis and Chronic Rhinosinusitis. In: Akdis CA, Hellings P, Agache I, editors. Published by the European Academy of Allergy and Clinical Immunology; 2015, pp 197–199. http://eaaci.org/globalatlas/ENT_Atlas_web.pdf. Accessed 20 Jul 2015. Currently, only CYSLT1 receptor antagonist are recommended as add-on therapy of allergic rhinitis (AR); montelukast is the best studied one and its efficacy seems better for moderate to severe persistent disease. Sanak M. Antileukotrienes in the treatment of allergic rhinitis. Global Atlas Of Allergic Rhinitis and Chronic Rhinosinusitis. In: Akdis CA, Hellings P, Agache I, editors. Published by the European Academy of Allergy and Clinical Immunology; 2015, pp 197–199. http://​eaaci.​org/​globalatlas/​ENT_​Atlas_​web.​pdf. Accessed 20 Jul 2015. Currently, only CYSLT1 receptor antagonist are recommended as add-on therapy of allergic rhinitis (AR); montelukast is the best studied one and its efficacy seems better for moderate to severe persistent disease.
13.
Zurück zum Zitat Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin intolerant asthma. J Clin Invest. 1998;101:834–46.PubMedCentralCrossRefPubMed Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin intolerant asthma. J Clin Invest. 1998;101:834–46.PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Adamjee J, Suh YJ, Park HS, et al. Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. J Pathol. 2006;209:392–9.CrossRefPubMed Adamjee J, Suh YJ, Park HS, et al. Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. J Pathol. 2006;209:392–9.CrossRefPubMed
15.
Zurück zum Zitat Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991;143:1025–9.CrossRefPubMed Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991;143:1025–9.CrossRefPubMed
16.
Zurück zum Zitat Corrigan C, Mallett K, Ying S, et al. Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J Allergy Clin Immunol. 2005;115:316–22.CrossRefPubMed Corrigan C, Mallett K, Ying S, et al. Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J Allergy Clin Immunol. 2005;115:316–22.CrossRefPubMed
17.
Zurück zum Zitat Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in asprinsensitive rhinosinusitis. N Engl J Med. 2002;347:1493–9.CrossRefPubMed Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in asprinsensitive rhinosinusitis. N Engl J Med. 2002;347:1493–9.CrossRefPubMed
18.
Zurück zum Zitat Nonaka Y, Hiramoto T, Fujita N. Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun. 2005;337:281–8.CrossRefPubMed Nonaka Y, Hiramoto T, Fujita N. Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun. 2005;337:281–8.CrossRefPubMed
19.
Zurück zum Zitat Paruchuri S, Tashimo H, Feng C, et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med. 2009;206:2543–55.PubMedCentralCrossRefPubMed Paruchuri S, Tashimo H, Feng C, et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med. 2009;206:2543–55.PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Maekawa A, Kanaoka Y, Xing W, et al. Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A. 2008;105:16695–700.PubMedCentralCrossRefPubMed Maekawa A, Kanaoka Y, Xing W, et al. Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A. 2008;105:16695–700.PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Steinke JW, Kennedy JL. Leukotriene inhibitors in sinusitis. Curr Infect Dis Rep. 2012;14:147–54.CrossRef Steinke JW, Kennedy JL. Leukotriene inhibitors in sinusitis. Curr Infect Dis Rep. 2012;14:147–54.CrossRef
22.
Zurück zum Zitat Steinke JW, Bradley D, Arango P, et al. Cytseinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. J Allergy Clin Immunol. 2003;111:342–9.CrossRefPubMed Steinke JW, Bradley D, Arango P, et al. Cytseinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. J Allergy Clin Immunol. 2003;111:342–9.CrossRefPubMed
23.
Zurück zum Zitat Bachert C, Wagenmann M, Hauser U, et al. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol. 1997;99:837–42.CrossRefPubMed Bachert C, Wagenmann M, Hauser U, et al. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol. 1997;99:837–42.CrossRefPubMed
24.
Zurück zum Zitat Bachert C, Gevaert P, van Cauwenberge P. Nasal polyposis—a new concept on the formation of polyps. ACI Int. 1999;11:130–5. Bachert C, Gevaert P, van Cauwenberge P. Nasal polyposis—a new concept on the formation of polyps. ACI Int. 1999;11:130–5.
25.
Zurück zum Zitat Elovic A, Wong DT, Weller PF, et al. Expression of transforming growth factors-alpha and beta 1 messenger RNA and product by eosinophils in nasal polyps. J Allergy Clin Immunol. 1994;93:864–9.CrossRefPubMed Elovic A, Wong DT, Weller PF, et al. Expression of transforming growth factors-alpha and beta 1 messenger RNA and product by eosinophils in nasal polyps. J Allergy Clin Immunol. 1994;93:864–9.CrossRefPubMed
26.
Zurück zum Zitat Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006;61:1280–9.CrossRefPubMed Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006;61:1280–9.CrossRefPubMed
27.
Zurück zum Zitat Minshall EM, Cameron L, Lavigne F, et al. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. Am J Resp Cell Mol Biol. 1997;17:683–90.CrossRef Minshall EM, Cameron L, Lavigne F, et al. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. Am J Resp Cell Mol Biol. 1997;17:683–90.CrossRef
28.
Zurück zum Zitat Hamilos DL, Leung DYM, Huston DP, et al. GM-CSF, IL-5, and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis. Clin Exp Allergy. 1998;28:1145–52.CrossRefPubMed Hamilos DL, Leung DYM, Huston DP, et al. GM-CSF, IL-5, and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis. Clin Exp Allergy. 1998;28:1145–52.CrossRefPubMed
29.••
Zurück zum Zitat Pérez-Novo CA, Watelet JB, Claeys C, et al. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol. 2005;115(6):1189–96. Expression of PGs and LTs in chronic rhinosinusitis phenotypes. CrossRefPubMed Pérez-Novo CA, Watelet JB, Claeys C, et al. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol. 2005;115(6):1189–96. Expression of PGs and LTs in chronic rhinosinusitis phenotypes. CrossRefPubMed
30.
Zurück zum Zitat Ulualp SO, Sterman BM, Toohill RJ. Antileukotriene therapy for the relief of sinus symptoms in aspirin triad disease. Ear Nose Throat J. 1999;78:604–16.PubMed Ulualp SO, Sterman BM, Toohill RJ. Antileukotriene therapy for the relief of sinus symptoms in aspirin triad disease. Ear Nose Throat J. 1999;78:604–16.PubMed
31.
Zurück zum Zitat Parnes SM, Chuma AV. Acute effects of antileukotrienes on sinonasal polyposis and sinusitis. Ear Nose Throat J. 2000;79:18–25.PubMed Parnes SM, Chuma AV. Acute effects of antileukotrienes on sinonasal polyposis and sinusitis. Ear Nose Throat J. 2000;79:18–25.PubMed
32.
Zurück zum Zitat Kutting B, Nieschalk M, Brehler R. A new concept for treatment of sinonasal polyposis. Allergy. 2000;55:1091–2.CrossRefPubMed Kutting B, Nieschalk M, Brehler R. A new concept for treatment of sinonasal polyposis. Allergy. 2000;55:1091–2.CrossRefPubMed
33.••
Zurück zum Zitat Mullol J, Callejas FB, Méndez-Arancibia E, et al. Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival. J Biol Regul Homeost Agents. 2010;24(4):403–11. Antiinflammatory effect of montelukast in nasal mucosa/polyp epithelial cells cytokine secretion and eosinophil survival. PubMed Mullol J, Callejas FB, Méndez-Arancibia E, et al. Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival. J Biol Regul Homeost Agents. 2010;24(4):403–11. Antiinflammatory effect of montelukast in nasal mucosa/polyp epithelial cells cytokine secretion and eosinophil survival. PubMed
34.
Zurück zum Zitat Ragab S, Parikh A, Darby YC, Scadding GK. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy. 2001;31:1385–91.CrossRefPubMed Ragab S, Parikh A, Darby YC, Scadding GK. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy. 2001;31:1385–91.CrossRefPubMed
35.
Zurück zum Zitat Grundmann T, Topfner M. Treatment of ASS-associated polyposis (ASSAP) with a cysteinyl leukotriene receptor antagonist—a prospective drug study on its antiinflammatory effects. Laryngorhinootologie. 2001;80:576–82.CrossRefPubMed Grundmann T, Topfner M. Treatment of ASS-associated polyposis (ASSAP) with a cysteinyl leukotriene receptor antagonist—a prospective drug study on its antiinflammatory effects. Laryngorhinootologie. 2001;80:576–82.CrossRefPubMed
36.
Zurück zum Zitat Mostafa BE, Abdel Hay H, Mohammed HE, Yamani M. Role of leukotriene inhibitors in the postoperative management of nasal polyps. ORL J Otorhinolaryngol Relat Spec. 2005;67:148–53.CrossRefPubMed Mostafa BE, Abdel Hay H, Mohammed HE, Yamani M. Role of leukotriene inhibitors in the postoperative management of nasal polyps. ORL J Otorhinolaryngol Relat Spec. 2005;67:148–53.CrossRefPubMed
37.
Zurück zum Zitat Kieff DA, Busaba NY. Efficacy of montelukast in the treatment of nasal polyposis. Ann Otol Rhinol Laryngol. 2005;114:941–5.CrossRefPubMed Kieff DA, Busaba NY. Efficacy of montelukast in the treatment of nasal polyposis. Ann Otol Rhinol Laryngol. 2005;114:941–5.CrossRefPubMed
38.••
39.•
Zurück zum Zitat Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;(23):3 p preceding table of contents, 1–298. This supplement reported that antileukotrienes were not recommended for adults or children with chronic rhinosinusitis without nasal polyps. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;(23):3 p preceding table of contents, 1–298. This supplement reported that antileukotrienes were not recommended for adults or children with chronic rhinosinusitis without nasal polyps.
40.
Zurück zum Zitat Majak P, Stelmach I. Should all children with asthma be treated with antileukotrienes—a review of clinical trials. Post Dermatol Alergol 2009; XXVI, 5: 313–314. Majak P, Stelmach I. Should all children with asthma be treated with antileukotrienes—a review of clinical trials. Post Dermatol Alergol 2009; XXVI, 5: 313–314.
42.
Zurück zum Zitat Zhao Y, Han S, Shang J, Zhao X, Pu R, Shi L. Effectiveness of drug treatment strategies to prevent asthma exacerbations and increase symptom-free days in asthmatic children: a network meta-analysis. J Asthma. 2015;10:1–12.CrossRef Zhao Y, Han S, Shang J, Zhao X, Pu R, Shi L. Effectiveness of drug treatment strategies to prevent asthma exacerbations and increase symptom-free days in asthmatic children: a network meta-analysis. J Asthma. 2015;10:1–12.CrossRef
43.••
Zurück zum Zitat Rank MA, Gionfriddo MR, Pongdee T, Volcheck GW, Li JT, Hagan CR, et al. Stepping down from inhaled corticosteroids with leukotriene inhibitors in asthma: a systematic review and meta-analysis. Allergy Asthma Proc. 2015;36(3):200–5. doi:10.2500/aap.2015.36.3839. This meta-analysis suggested that only one study addressed the risk of substitution of leukotriene receptor antagonists (LTRA) for inhaled corticosteroid (ICS) in stable asthma. PubMedCentralCrossRefPubMed Rank MA, Gionfriddo MR, Pongdee T, Volcheck GW, Li JT, Hagan CR, et al. Stepping down from inhaled corticosteroids with leukotriene inhibitors in asthma: a systematic review and meta-analysis. Allergy Asthma Proc. 2015;36(3):200–5. doi:10.​2500/​aap.​2015.​36.​3839. This meta-analysis suggested that only one study addressed the risk of substitution of leukotriene receptor antagonists (LTRA) for inhaled corticosteroid (ICS) in stable asthma. PubMedCentralCrossRefPubMed
44.
Zurück zum Zitat Drazen J. Clinical pharmacology of leukotriene receptor antagonists and 5 lipoxygenase inhibitors. Am J Respir Crit Care Med. 1998;157:233–7.CrossRef Drazen J. Clinical pharmacology of leukotriene receptor antagonists and 5 lipoxygenase inhibitors. Am J Respir Crit Care Med. 1998;157:233–7.CrossRef
45.
Zurück zum Zitat Philip G, Williams-Herman D, Patel P, et al. Efficacy of montelukast for treating perennial allergic rhinitis. Allergy Asthma Proc. 2007;28:296–304.CrossRefPubMed Philip G, Williams-Herman D, Patel P, et al. Efficacy of montelukast for treating perennial allergic rhinitis. Allergy Asthma Proc. 2007;28:296–304.CrossRefPubMed
46.
47.
Zurück zum Zitat Ernst P, FitzGerald JM, Spier S. Canadian asthma consensus conference: summary of recommendations. Can Respir J. 1996;3:89–100. Ernst P, FitzGerald JM, Spier S. Canadian asthma consensus conference: summary of recommendations. Can Respir J. 1996;3:89–100.
48.
Zurück zum Zitat Ducharme FM, Hicks GC. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2002;3, CD002314.PubMed Ducharme FM, Hicks GC. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2002;3, CD002314.PubMed
49.
Zurück zum Zitat Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention NIH Pub. No 02–3659, January 1995. Updated December 2011. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention NIH Pub. No 02–3659, January 1995. Updated December 2011.
50.
Zurück zum Zitat Walia M, Lodha R, Kabra SK. Montelukast in pediatric asthma management. Indian J Pediatr. 2006;73:275–82.CrossRefPubMed Walia M, Lodha R, Kabra SK. Montelukast in pediatric asthma management. Indian J Pediatr. 2006;73:275–82.CrossRefPubMed
51.
Zurück zum Zitat Amlani S, Nadarajah T, McIvor RA. Montelukast for the treatment of asthma in the adult population. Expert Opin Pharmacother. 2011;12:2119–28.CrossRefPubMed Amlani S, Nadarajah T, McIvor RA. Montelukast for the treatment of asthma in the adult population. Expert Opin Pharmacother. 2011;12:2119–28.CrossRefPubMed
52.
Zurück zum Zitat Fritscher LG, Rodrigues MT, Zamel N, et al. The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma. Respir Med. 2009;103:296–300.CrossRefPubMed Fritscher LG, Rodrigues MT, Zamel N, et al. The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma. Respir Med. 2009;103:296–300.CrossRefPubMed
53.
Zurück zum Zitat Bhatt JM, Smyth AR. The management of pre-school wheeze. Paediatr Respir Rev. 2011;12(1):70–7.CrossRefPubMed Bhatt JM, Smyth AR. The management of pre-school wheeze. Paediatr Respir Rev. 2011;12(1):70–7.CrossRefPubMed
54.
Zurück zum Zitat Pedersen S, Agertoft L, Williams-Herman D, et al. Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children. Pediatr Pulmonol. 2007;42:838–43.CrossRefPubMed Pedersen S, Agertoft L, Williams-Herman D, et al. Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children. Pediatr Pulmonol. 2007;42:838–43.CrossRefPubMed
55.
Zurück zum Zitat Hildebrand K. Exercise-induced bronchoconstriction. Pneumonol Alergol Pol. 2011;79:39–47.PubMed Hildebrand K. Exercise-induced bronchoconstriction. Pneumonol Alergol Pol. 2011;79:39–47.PubMed
56.
57.••
Zurück zum Zitat Schäper C, Noga O, Koch B, et al. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol. 2011;21(1):51–8. Antiinflammatory properties of montelukast in patients with asthma and CRSwNP. PubMed Schäper C, Noga O, Koch B, et al. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol. 2011;21(1):51–8. Antiinflammatory properties of montelukast in patients with asthma and CRSwNP. PubMed
58.
Zurück zum Zitat Liang M, Xu R, Xu G. Recent advances in allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015;29(3):202–6.PubMed Liang M, Xu R, Xu G. Recent advances in allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015;29(3):202–6.PubMed
59.
Zurück zum Zitat Lu Y, Yin M, Cheng L. Meta-analysis of leukotriene receptor antagonist montelukast in the treatment of allergic rhinitis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014;49(8):659–67.PubMed Lu Y, Yin M, Cheng L. Meta-analysis of leukotriene receptor antagonist montelukast in the treatment of allergic rhinitis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014;49(8):659–67.PubMed
60.•
Zurück zum Zitat Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg. 2015;152(1 Suppl):S1–43. doi:10.1177/0194599814561600. This paper reported that the LTRA montelukast is FDA-approved for the treatment of symptoms of seasonal AR in adults and paediatric patients 2 years of age and older and perennial AR in adults and paediatric patients 6 months of age and older. CrossRefPubMed Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg. 2015;152(1 Suppl):S1–43. doi:10.​1177/​0194599814561600​. This paper reported that the LTRA montelukast is FDA-approved for the treatment of symptoms of seasonal AR in adults and paediatric patients 2 years of age and older and perennial AR in adults and paediatric patients 6 months of age and older. CrossRefPubMed
61.
Zurück zum Zitat Gonyeau MJ, Partisano AM. A clinical review of montelukast in the treatment of seasonal allergic rhinitis. Formulary. 2003;38:368–78. Gonyeau MJ, Partisano AM. A clinical review of montelukast in the treatment of seasonal allergic rhinitis. Formulary. 2003;38:368–78.
62.
Zurück zum Zitat Grainger J, Drake-Lee A. Montelukast in allergic rhinitis: a systematic review and meta-analysis. Clin Otolaryngol. 2006;31:360–7.CrossRefPubMed Grainger J, Drake-Lee A. Montelukast in allergic rhinitis: a systematic review and meta-analysis. Clin Otolaryngol. 2006;31:360–7.CrossRefPubMed
63.
Zurück zum Zitat Rodrigo GJ, Yañez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol. 2006;96:779–86.CrossRefPubMed Rodrigo GJ, Yañez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol. 2006;96:779–86.CrossRefPubMed
64.
Zurück zum Zitat Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs. 2007;67:887–901.CrossRefPubMed Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs. 2007;67:887–901.CrossRefPubMed
65.
Zurück zum Zitat Wilson AM, O’Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med. 2004;116:338–44.CrossRefPubMed Wilson AM, O’Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med. 2004;116:338–44.CrossRefPubMed
66.
Zurück zum Zitat Mucha SM, de Tineo M, Naclerio RM, et al. Comparison of montelukast and pseudoephedrine in the treatment of allergic rhinitis. Arch Otolaryngol Head Neck Surg. 2006;132:164–72.CrossRefPubMed Mucha SM, de Tineo M, Naclerio RM, et al. Comparison of montelukast and pseudoephedrine in the treatment of allergic rhinitis. Arch Otolaryngol Head Neck Surg. 2006;132:164–72.CrossRefPubMed
67.
Zurück zum Zitat Baena-Cagnani CE, Berger WE, DuBuske LM, et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol. 2003;130:307–13.CrossRefPubMed Baena-Cagnani CE, Berger WE, DuBuske LM, et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol. 2003;130:307–13.CrossRefPubMed
68.
Zurück zum Zitat Perry TT, Corren J, Philip G, et al. Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure. Ann Allergy Asthma Immunol. 2004;93:431–8.CrossRefPubMed Perry TT, Corren J, Philip G, et al. Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure. Ann Allergy Asthma Immunol. 2004;93:431–8.CrossRefPubMed
69.
Zurück zum Zitat Papadopoulos NG, Philip G, Giezek H, et al. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity. J Asthma. 2009;46:413–20.CrossRefPubMed Papadopoulos NG, Philip G, Giezek H, et al. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity. J Asthma. 2009;46:413–20.CrossRefPubMed
70.
Zurück zum Zitat Philip G, Nayak AS, Berger WE. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin. 2004;20:1549–58.CrossRefPubMed Philip G, Nayak AS, Berger WE. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin. 2004;20:1549–58.CrossRefPubMed
71.
Zurück zum Zitat Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol. 2009;44:568–79.CrossRefPubMed Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol. 2009;44:568–79.CrossRefPubMed
72.
Zurück zum Zitat Philip G, Hustad CM, Malice MP, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol. 2009;124:699–706.CrossRefPubMed Philip G, Hustad CM, Malice MP, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol. 2009;124:699–706.CrossRefPubMed
75.
Zurück zum Zitat Hay J, Jhaveri M, Tangirala M, et al. Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment. Allergy Asthma Proc. 2009;30:634–42.CrossRefPubMed Hay J, Jhaveri M, Tangirala M, et al. Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment. Allergy Asthma Proc. 2009;30:634–42.CrossRefPubMed
76.
Zurück zum Zitat Di Lorenzo G, Pacor ML, Pellitteri ME, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004;34(2):259–67.CrossRefPubMed Di Lorenzo G, Pacor ML, Pellitteri ME, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004;34(2):259–67.CrossRefPubMed
77.
Zurück zum Zitat Modgill V, Badyal DK, Verghese A. Efficacy and safety of montelukast add-on therapy in allergic rhinitis. Methods Find Exp Clin Pharmacol. 2010;32(9):669–74.CrossRefPubMed Modgill V, Badyal DK, Verghese A. Efficacy and safety of montelukast add-on therapy in allergic rhinitis. Methods Find Exp Clin Pharmacol. 2010;32(9):669–74.CrossRefPubMed
78.
Zurück zum Zitat Esteitie R, de Tineo M, Naclerio RM, et al. Effect of the addition of montelukast to fluticasone proprionate for the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2010;105:155–61.CrossRefPubMed Esteitie R, de Tineo M, Naclerio RM, et al. Effect of the addition of montelukast to fluticasone proprionate for the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2010;105:155–61.CrossRefPubMed
79.
80.
Zurück zum Zitat Simon RA. The role of leukotrienes and antileukotriene agents in the pathogenesis and treatment of allergic rhinitis. Clin Rev Allergy Immunol. 1999;17:271–5.CrossRefPubMed Simon RA. The role of leukotrienes and antileukotriene agents in the pathogenesis and treatment of allergic rhinitis. Clin Rev Allergy Immunol. 1999;17:271–5.CrossRefPubMed
81.
Zurück zum Zitat Naclerio RM, Baroody FM, Togias AG. The role of leukotrienes in allergic rhinitis: a review. Am Rev Respir Dis. 1991;143:S91–5.CrossRefPubMed Naclerio RM, Baroody FM, Togias AG. The role of leukotrienes in allergic rhinitis: a review. Am Rev Respir Dis. 1991;143:S91–5.CrossRefPubMed
82.
Zurück zum Zitat Saito H, Morikawa H, Howie K, et al. Effects of a cysteinyl leukotriene receptor antagonist on eosinophil recruitment in experimental allergic rhinitis. Immunology. 2004;113:246–52.PubMedCentralCrossRefPubMed Saito H, Morikawa H, Howie K, et al. Effects of a cysteinyl leukotriene receptor antagonist on eosinophil recruitment in experimental allergic rhinitis. Immunology. 2004;113:246–52.PubMedCentralCrossRefPubMed
83.
Zurück zum Zitat Ho CY, Tan CT. Comparison of antileukotrienes and antihistamines in the treatment of allergic rhinitis. Am J Rhinol. 2007;21(4):439–43.CrossRefPubMed Ho CY, Tan CT. Comparison of antileukotrienes and antihistamines in the treatment of allergic rhinitis. Am J Rhinol. 2007;21(4):439–43.CrossRefPubMed
85.
Zurück zum Zitat Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of one linked airway disease. Ann Allergy Asthma Immunol. 2000;84:176–85.CrossRefPubMed Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of one linked airway disease. Ann Allergy Asthma Immunol. 2000;84:176–85.CrossRefPubMed
86.
Zurück zum Zitat Roquet A, Dahlen B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med. 1997;155:1856–63.CrossRefPubMed Roquet A, Dahlen B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med. 1997;155:1856–63.CrossRefPubMed
87.
Zurück zum Zitat Fujita M, Nakagawa N, Yonetomi YT, et al. Cysteinyl leukotrienes induce nasal symptoms of allergic rhinitis via a receptor-mediated mechanism in guinea pigs. Jpn J Pharmacol. 1997;75:355–62.CrossRefPubMed Fujita M, Nakagawa N, Yonetomi YT, et al. Cysteinyl leukotrienes induce nasal symptoms of allergic rhinitis via a receptor-mediated mechanism in guinea pigs. Jpn J Pharmacol. 1997;75:355–62.CrossRefPubMed
88.
Zurück zum Zitat Fujita M, Yonetomi Y, Shimouchi K, et al. Involvement of cysteinyl leukotrienes in biphasic increase of nasal airway resistance of antigen-induced rhinitis in guinea pigs. Eur J Pharmacol. 1999;369:349–56.CrossRefPubMed Fujita M, Yonetomi Y, Shimouchi K, et al. Involvement of cysteinyl leukotrienes in biphasic increase of nasal airway resistance of antigen-induced rhinitis in guinea pigs. Eur J Pharmacol. 1999;369:349–56.CrossRefPubMed
89.
Zurück zum Zitat Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy. 1986;16:289–97.CrossRefPubMed Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy. 1986;16:289–97.CrossRefPubMed
91.
Zurück zum Zitat Figueroa DJ, Borish L, Baramki D, Philip G, Austin CP, Evans JF. Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis. Clin Exp Allergy. 2003;33:1380–8.CrossRefPubMed Figueroa DJ, Borish L, Baramki D, Philip G, Austin CP, Evans JF. Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis. Clin Exp Allergy. 2003;33:1380–8.CrossRefPubMed
92.
Zurück zum Zitat Shirasaki H, Kanaizumi E, Watanabe K, et al. Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa. Clin Exp Allergy. 2002;32:1007–12.CrossRefPubMed Shirasaki H, Kanaizumi E, Watanabe K, et al. Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa. Clin Exp Allergy. 2002;32:1007–12.CrossRefPubMed
93.
Zurück zum Zitat Volovitz B, Osur SL, Bernstein JM, Ogra PL. Leukotriene C4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children. J Allergy Clin Immunol. 1988;82:414–8.CrossRefPubMed Volovitz B, Osur SL, Bernstein JM, Ogra PL. Leukotriene C4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children. J Allergy Clin Immunol. 1988;82:414–8.CrossRefPubMed
94.
Zurück zum Zitat Sacre Hazouri JA. Leukotriene antagonists in the treatment of allergic rhinitis and comorbidities. Rev Alerg Mex. 2008;55(4):164–75.PubMed Sacre Hazouri JA. Leukotriene antagonists in the treatment of allergic rhinitis and comorbidities. Rev Alerg Mex. 2008;55(4):164–75.PubMed
95.
Zurück zum Zitat Donnelly A, Glass M, Minkwitz M, et al. The leukotrieneD4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med. 1995;151:1734–9.CrossRefPubMed Donnelly A, Glass M, Minkwitz M, et al. The leukotrieneD4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med. 1995;151:1734–9.CrossRefPubMed
96.
Zurück zum Zitat Grossman J, Ratner P, Nathan R, et al. Pranlukast (UltairTM, SB 205312, ONO-1078), an oral leukotriene receptor antagonist, relieves symptoms in patients with seasonal allergic rhinitis (SAR). J Allergy Clin Immunol. 1997;99:S443.CrossRef Grossman J, Ratner P, Nathan R, et al. Pranlukast (UltairTM, SB 205312, ONO-1078), an oral leukotriene receptor antagonist, relieves symptoms in patients with seasonal allergic rhinitis (SAR). J Allergy Clin Immunol. 1997;99:S443.CrossRef
97.
Zurück zum Zitat Malmstrom K, Hampel F, Philip G, et al. Montelukast in the treatment of spring allergic rhinitis in a large, double-blind, randomized, placebo-controlled study. J Allergy Clin Immunol. 2001;107:S157. Malmstrom K, Hampel F, Philip G, et al. Montelukast in the treatment of spring allergic rhinitis in a large, double-blind, randomized, placebo-controlled study. J Allergy Clin Immunol. 2001;107:S157.
98.
Zurück zum Zitat Pullerits T, Praks L, Skoogh B, et al. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Care Med. 1999;159:1814–8.CrossRef Pullerits T, Praks L, Skoogh B, et al. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Care Med. 1999;159:1814–8.CrossRef
99.
Zurück zum Zitat Meltzer E, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2000;105:917–22.CrossRefPubMed Meltzer E, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2000;105:917–22.CrossRefPubMed
100.
Zurück zum Zitat Lis K, Malmstrom K, Nayak A, et al. Treatment of fall allergic rhinitis with montelukast alone or in combination with loratadine in a multicenter, double-blind, randomized, placebo-controlled study. J Allergy Clin Immunol. 2001;107:S158. Lis K, Malmstrom K, Nayak A, et al. Treatment of fall allergic rhinitis with montelukast alone or in combination with loratadine in a multicenter, double-blind, randomized, placebo-controlled study. J Allergy Clin Immunol. 2001;107:S158.
Metadaten
Titel
Antileukotrienes in Upper Airway Inflammatory Diseases
verfasst von
Cemal Cingi
Nuray Bayar Muluk
Kagan Ipci
Ethem Şahin
Publikationsdatum
01.11.2015
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 11/2015
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-015-0564-7

Weitere Artikel der Ausgabe 11/2015

Current Allergy and Asthma Reports 11/2015 Zur Ausgabe

Allergens (RK Bush and JA Woodfolk, Section Editors)

New Insights into Ragweed Pollen Allergens

Allergens (RK Bush and JA Woodfolk, Section Editors)

The Role of the Skin Microbiome in Atopic Dermatitis

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.